Related references
Note: Only part of the references are listed.Pharmacokinetic-Pharmacodynamic Modeling of the Anti-Tumor Effect of Sunitinib Combined with Dopamine in the Human Non-Small Cell Lung Cancer Xenograft
Fangran Hao et al.
PHARMACEUTICAL RESEARCH (2017)
Cancer Statistics, 2017
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2017)
Preclinical PK/PD model for combined administration of erlotinib and sunitinib in the treatment of A549 human NSCLC xenograft mice
Jing-yun Li et al.
ACTA PHARMACOLOGICA SINICA (2016)
Effects of Psoralen as an Anti-tumor Agent in Human Breast Cancer MCF-7/ADR Cells
Xiaohong Wang et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2016)
In Vitro Kinetic Characterization of Axitinib Metabolism
Michael A. Zientek et al.
DRUG METABOLISM AND DISPOSITION (2016)
Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cells
Siyuan Wang et al.
BIOCHEMICAL PHARMACOLOGY (2015)
Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma
Lei Lu et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Molecular Markers for Breast Cancer Diagnosis, Prognosis and Targeted Therapy
Julie E. Lang et al.
JOURNAL OF SURGICAL ONCOLOGY (2015)
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses
E. E. W. Cohen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells
Edmund Chinchar et al.
VASCULAR CELL (2014)
Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model
Qiong Wu et al.
ACTA PHARMACOLOGICA SINICA (2013)
Targeted Therapy for Breast Cancer
Ali Mohamed et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model
Kexiong Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between Erlotinib and Gemcitabine
Mengyao Li et al.
PHARMACEUTICAL RESEARCH (2013)
In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions
Eric L. Reyner et al.
DRUG METABOLISM AND DISPOSITION (2013)
Target Practice: Modeling Tumors with Stem Cells
Kai Liu et al.
CELL (2012)
Chemotherapy-Resistant Metastatic Breast Cancer
Carrie Marquette et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2012)
Stem cells in breast tumours: Are they ready for the clinic?
Matthew P. Ablett et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer
Jean-Philippe Spano et al.
INVESTIGATIONAL NEW DRUGS (2012)
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Sarah J. Conley et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma
John Fruehauf et al.
CLINICAL CANCER RESEARCH (2011)
The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation
Wenlei Jiang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2011)
Randomized, Placebo-Controlled, Double-Blind, Phase II Study of Axitinib Plus Docetaxel Versus Docetaxel Plus Placebo in Patients With Metastatic Breast Cancer
Hope S. Rugo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeting Breast Cancer Stem Cells
Suling Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer Metastasis Directly Eradicated by Targeted Therapy With a Modified Salmonella typhimurium
Katsuhiro Hayashi et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2009)
Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
Joan H. Schiller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Modeling of tumor growth and anticancer effects of combination therapy
Gilbert Koch et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2009)
Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
Dana D. Hu-Lowe et al.
CLINICAL CANCER RESEARCH (2008)
Internal Mammary Nodes in Breast Cancer: Diagnosis and Implications for Patient Management - A Systematic Review
Ronald C. Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer:: an open-label randomised phase II study
Jean-Philippe Spano et al.
LANCET (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study
Olivier Rixe et al.
LANCET ONCOLOGY (2007)
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging
Lisa J. Wilmes et al.
MAGNETIC RESONANCE IMAGING (2007)
Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents
M Simeoni et al.
CANCER RESEARCH (2004)
Analysis of logistic growth models
A Tsoularis et al.
MATHEMATICAL BIOSCIENCES (2002)
Endocrine-responsive breast cancer and strategies for combating resistance
S Ali et al.
NATURE REVIEWS CANCER (2002)
Share Paper
